Literature DB >> 10741905

Pentoxifylline inhibits ICAM-1 expression and chemokine production induced by proinflammatory cytokines in human pulmonary epithelial cells.

T Krakauer1.   

Abstract

Airway epithelium participates in inflammatory reactions by producing chemokines and expressing cell-surface adhesion molecules which aid in the selective recruitment of effector cells. Previous studies showed that proinflammatory cytokines, interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF alpha), induce surface expression of intercellular adhesion molecule 1 (ICAM-1) and the production of the chemokines interleukin 8 (IL-8) and monocyte chemoattractant protein (MCP-1) on pulmonary epithelial cell lines in vitro. In this study, the dose response of four cytokines, IL-1alpha, IL-1beta, TNF alpha and TNF beta, in inducing ICAM-1 expression and production of IL-8 and MCP-1 on pulmonary A549 epithelial cells was examined. Both IL-1alpha and IL-1beta induced ICAM-1 expression and IL-8 and MCP-1 production at lower doses than TNF alpha or TNF beta. Pentoxifylline, an anti-inflammatory agent used to treat vascular diseases, was tested for its ability to inhibit the activation of airway epithelial cells by these cytokines. Pentoxifylline completely inhibited the surface expression of ICAM-1 and the production of IL-8 and MCP-1 by cytokine-activated epithelial cells. As elevated levels of chemokines are often present in bronchial lavage fluids of patients suffering from various acute respiratory diseases, pentoxifylline may be useful for preventing the rapid development of immune reactions leading to lung injury.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741905     DOI: 10.1016/s0162-3109(99)00186-1

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  11 in total

Review 1.  Small therapeutic molecules for the treatment of inflammatory bowel disease.

Authors:  S J H van Deventer
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 2.  Lung inflammatory response syndrome after cardiac-operations and treatment of lornoxicam.

Authors:  Kosmas Tsakiridis; Andreas Mpakas; George Kesisis; Stamatis Arikas; Michael Argyriou; Stavros Siminelakis; Paul Zarogoulidis; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Theodora Tsiouda; Eirini Sarika; Ioanna Katamoutou; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

3.  Effect of lornoxicam in lung inflammatory response syndrome after operations for cardiac surgery with cardiopulmonary bypass.

Authors:  Kosmas Tsakiridis; Paul Zarogoulidis; Giorgos Vretzkakis; Dimitris Mikroulis; Andreas Mpakas; Georgios Kesisis; Stamatis Arikas; Alexandros Kolettas; Giorgios Moschos; Nikolaos Katsikogiannis; Nikolaos Machairiotis; Theodora Tsiouda; Stavros Siminelakis; Thomas Beleveslis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

4.  Pentoxifylline influences the autocrine function of organ cultured donor corneas and enhances endothelial cell survival.

Authors:  A C Ventura; M Böhnke
Journal:  Br J Ophthalmol       Date:  2001-09       Impact factor: 4.638

5.  Toxicological analysis of limonene reaction products using an in vitro exposure system.

Authors:  Stacey E Anderson; Shahana S Khurshid; B Jean Meade; Ewa Lukomska; J R Wells
Journal:  Toxicol In Vitro       Date:  2012-12-07       Impact factor: 3.500

6.  Alpha-4/beta-1 and alpha-L/beta-2 integrins mediate cytokine induced lung leukocyte-epithelial adhesion and injury.

Authors:  L A Parmley; N D Elkins; M A Fini; Y-E Liu; J E Repine; R M Wright
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

Review 7.  Immunological mechanisms of pentoxifylline in chronic heart failure.

Authors:  Steven M Shaw; Mohammed K H Shah; Simon G Williams; James E Fildes
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

Review 8.  Management of Lower Extremity Pain from Chronic Venous Insufficiency: A Comprehensive Review.

Authors:  Vwaire Orhurhu; Robert Chu; Katherine Xie; Ghislain N Kamanyi; Bisola Salisu; Mariam Salisu-Orhurhu; Ivan Urits; Rachel J Kaye; Jamal Hasoon; Omar Viswanath; Aaron J Kaye; Jay Karri; Zwade Marshall; Alan D Kaye; Dua Anahita
Journal:  Cardiol Ther       Date:  2021-03-11

9.  Harnessing adenosine A2A receptors as a strategy for suppressing the lung inflammation and thrombotic complications of COVID-19: Potential of pentoxifylline and dipyridamole.

Authors:  James J DiNicolantonio; Jorge Barroso-Aranda
Journal:  Med Hypotheses       Date:  2020-07-02       Impact factor: 1.538

10.  Measles-induced respiratory distress, air-leak and ARDS.

Authors:  M Piastra; R Onesimo; D De Luca; L Lancella; L Marzano; G De Rosa; D Pietrini; P Valentini; G Conti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2009-12-13       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.